Founded in 2005, Porton Pharma Solutions Ltd. is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for small molecule, Large molecule and Gene and Cell Therapies from pre-clinical to commercialization. As of June 30, 2023, we have a proven record for the delivery of more than 2600 projects and established cooperation with more than 800 global clients. With our 5000+ skilled employees working across 20+ sites around the globe, Porton is committed to becoming the most open, innovative and reliable pharmaceutical service platform in the world and enabling the public’s early access to good medicines. Porton is publicly listed on the Shenzhen Stock Exchange (Ticker: 300363).
With over 5000 customer-centric employees, operations and commercial offices across the US, EU and China, Porton Pharma Solutions/J-Star Research provides global pharmaceutical companies with innovative, reliable and end-to-end process R&D and GMP manufacturing services across small molecule APIs, TIDES, biologics and Gene & Cell Therapies.
We focus on the customer and have been recognized through awards by industry forums and global pharmaceutical companies for our process innovation, supply chain performance, and compliance with global Quality and EHS standards. We constantly strive for excellence and enable the public’s early access to good medicines.
-
所属行业
-
制药业
-
规模
-
5,001-10,000 人
-
总部
-
Beibei，Chongqing
-
类型
-
上市公司
-
创立
-
2005
